Acknowledgement
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1A6A1A03012862 and 2021R1I1A1A01041462).
References
- Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366, 1303-1314
- Bragazzi MC, Ridola L, Safarikia S et al (2018) New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol 31, 42-55
- Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33, 1353-1357
- Malhi H and Gores GJ (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45, 856-867
- Khan SA, Emadossadaty S, Ladep NG et al (2012) Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 56, 848-854
- Zhang S, Xiong H, Yang J and Yuan X (2021) Pan-cancer analysis reveals the multidimensional expression and prognostic and immunologic roles of VSTM2L in cancer. Front Mol Biosci 8, 792154
- Rossini L, Hashimoto Y, Suzuki H et al (2011) VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin. FASEB J 25, 1983-2000
- Liu H, Zhang Z, Zhen P and Zhou M (2021) High expression of VSTM2L induced resistance to chemoradiotherapy in rectal cancer through downstream IL-4 signaling. J Immunol Res 2021, 6657012
- Li Y, Zhang J, Cai Y et al (2023) VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer. Biochem Biophys Res Commun 658, 107-115
- Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17, 557-588
- Zhu J, Chen X, Liao Z, He C and Hu X (2015) TGFBI protein high expression predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol 8, 702-710
- Pajares MJ, Agorreta J, Salvo E et al (2014) TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br J Cancer 110, 1545-1551
- Macias RIR, Banales JM, Sangro B et al (2018) The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864, 1468-1477
- Miwa M, You G, Tanaka H et al (2014) Analysis of new biomarkers for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21, 397-398
- Sim W, Lee J and Choi C (2017) Robust method for identification of prognostic gene signatures from gene expression profiles. Sci Rep 7, 16926
- Lee J, Lee J, Sim W and Kim JH (2022) Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARgamma signalling pathway. Cell Oncol (Dordr) 45, 275-291
- Lee J, Kim E, Chong K et al (2022) Atypical induction of HIF-1alpha expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells. Cell Mol Life Sci 79, 537
- Lee J, Chong K, Lee J et al (2022) Differential dependency of human glioblastoma cells on vascular endothelial growth factor‑A signaling via neuropilin‑1. Int J Oncol 61, 122
- Lee J, Lee J, Yu H, Choi K and Choi C (2011) Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett 309, 145-150